ReviewExperimental and clinical psychopharmacology2016
Clinical applications of hallucinogens: A review.
Review in Experimental and clinical psychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.The Cochrane database of systematic reviews · 2024Pooled it
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.Journal of psychopharmacology (Oxford, England) · 2022Pooled it
- Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.Journal of psychoactive drugsPooled it
- Unusual experiences and early-onset psychosis associated to hallucinogen use in adolescents: a systematic review and meta-analysis.Child and adolescent psychiatry and mental health · 2026Review
- Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration.Journal of psychopharmacology (Oxford, England) · 2026Article
- Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Dialogues in clinical neuroscience · 2025Review
- Deconstructing the trip treatment: are hallucinogenic effects critical to the therapeutic benefits of psychedelics?NPP - digital psychiatry and neuroscience · 2025Review
- An international Delphi consensus for reporting of setting in psychedelic clinical trials.Nature medicine · 2025Article
- Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany.Scientific reports · 2025Article
- The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.Expert opinion on pharmacotherapy · 2025Review
- Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.Current pain and headache reports · 2025Review
- Article
- Article
- Perioperative considerations for patients exposed to hallucinogens.Regional anesthesia and pain medicine · 2024Review
- Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.Scientific reports · 2024Article
- Psychedelics and the treatment of eating disorders: considerations for future research and practice.Journal of eating disorders · 2024Article
- A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.Brain sciences · 2024Review
- Aggressive behaviours associated with MDMA and psychedelics: a narrative review.Acta neuropsychiatrica · 2024Review
- Magnesium-ibogaine therapy in veterans with traumatic brain injuries.Nature medicine · 2024Observational
- Examining the influence of team-based learning on medical students' comprehension and attitudes regarding psychedelic therapies.Dialogues in clinical neuroscience · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hallucinogens fall into several different classes, as broadly defined by pharmacological mechanism of action, and chemical structure. These include psychedelics, entactogens, dissociatives, and other atypical hallucinogens. Although these classes do not share a common primary mechanism of action, they do exhibit important similarities in their ability to occasion temporary but profound alterations of consciousness, involving acute changes in somatic, perceptual, cognitive, and affective processes. Such effects likely contribute to their recreational use. However, a growing body of evidence indicates that these drugs may have therapeutic applications beyond their potential for abuse. This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented. Information on each class is presented in turn, tracing relevant historical insights, highlighting similarities and differences between the classes from the molecular to the behavioral level, and presenting the most up-to-date information on clinically oriented research with these substances, with important ramifications for their potential therapeutic value. (PsycINFO Database Record
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.